Posted by admin | Posted in Health Info | Posted on 11-09-2011
When Rafael Matesanz speaks of the great challenges in transplantation, not only speaks of complex interventions, also of cell therapy.
Do you consider cell therapy as the vanguard of transplants?
Sure, the bioartificial organs are the background of the use of stem cells for transplantation. Spain is well positioned, working with a team from the University of Minnesota, to develop bioartificial hearts. We started to do so, the patient’s stem cells. It is a way forward, not tomorrow or the day after, but it is very interesting, because it can provide organs without depending on donations, and because immunosuppression is not needed, because they are made with the patient’s tissues. I think if some fieldwork will open new heights.
We talked long term …
Yes, it is difficult to set deadlines. Stem cells aroused many hopes and expectations. Have been achieved in 13 years many things, but perhaps more was expected of them. The important thing is to let researchers working quietly, without expecting great results in the short term. But at 5, 10 or 15 years, there will be significant results.
When Spain exports its model transplants outside, what do you teach?
Organization, I think the model of Spain has provided the professional system, which is whole structured. And train professionals from abroad. Now, for example, we will form a team in India. And people from Latin America.
This will try to combat organ trafficking …
We help countries to have a transplant and cut with this scourge. There is a disproportion between supply and demand. About 100,000 a year transplants in the world, but demand is one million.